Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma

Original Article

S.M. Castellino, Q. Pei, S.K. Parsons, D. Hodgson, K. McCarten, T. Horton, S. Cho, Y. Wu, A. Punnett, H. Dave, T.O. Henderson, B.S. Hoppe, A.-M. Charpentier, F.G. Keller, and K.M. Kelly

N Engl J Med 2022;387:1649-1660

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
11/02/2022
Course expires: 
11/03/2024
Take course

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Take course